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Agents to induce readthrough of premature termination codons (PTCs) are useful research tools and
potential therapeutics. Reporters used to detect PTC readthrough are gene-speciﬁc and thus are not
suited to for general assessment of readthrough activity or in cases where PTC-inactivated genes are
unknown. Here we describe a GFP-based reporter construct pMHG-W57⁄ which is capable of detect-
ing dose-dependent drug-induced PTC readthrough both by ﬂuorescence microscopy and ﬂow
cytometry. pMHG-W57⁄ may be used as a general indicator of PTC readthrough in living cells and
obviates the need for gene-speciﬁc recoding sequences in reporter constructs.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction antibiotics for several decades (e.g. neomycin, kanamycin, paromo-Almost one third of all heritable disorders result from prema-
ture termination codons (PTCs) mutations [1]. PTCs may result
from nonsense or frameshift mutations, as well as exon skipping
or splice site intron inclusions. Heritable disorders where prema-
ture stop codon mutations (TAA, TAG or TGA) commonly occur
include Duchenne muscular dystrophy (DMD) (10–20% of patients)
and cystic ﬁbrosis (CF) (2–5% of patients) [2], Furthermore, PTCs
may occur in tumor suppressor genes. In general, these mutations
result in the activation of nonsense mediated decay (NMD), where-
by PTC-containing mRNAs are targeted for rapid degradation. Inhi-
bition of NMD to uncover PTCs, called gene identiﬁcation by NMD
Inhibition (GINI), was ﬁrst described in colon cancer and used to
conﬁrm a known PTC in MLH1, among others [3]. Subsequent stud-
ies have successfully used this strategy to uncover inactivating
tumor suppressor mutations in colon and prostate cancer and in
melanoma [4–6].
Strategies for correction of PTCs have focused on the identiﬁca-
tion of compounds which allow the translational machinery to
overcome aberrant termination codons. One such class of com-
pounds are aminoglycosides, which have been widely used asal Societies. Published by Elsevier
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os).mycin) [7]. Aminoglycosides bind with high speciﬁcity to the 16S
ribosome in prokaryotes, resulting in altered ribosomal conforma-
tion and loss of codon–anticodon ﬁdelity. Loss of ﬁdelity causes
incorporation of incorrect amino acids at sense codons or failure
to recognize stop codons. Aminoglycoside speciﬁcity in prokary-
otes is mediated through adenine 1408 in the 16S ribosome. In
eukaryotic ribosomes, the corresponding nucleotide is a guanine,
resulting in lower binding afﬁnity. Consequently, higher doses of
aminoglycosides are required to affect protein translation in
eukaryotes (>10 times therapeutic dose in prokaryotes).
Many groups have demonstrated the ability of aminoglycoside
compounds to circumvent PTCs and restore synthesis of full-size
proteins. Both G-418 (geneticin) and gentamicin promote read-
through of nonsense mutations (R553X and G542X) in the cystic
ﬁbrosis transmembrane conductance regulator (CFTR), resulting
in full length protein expression and restoration of cyclic-AMP acti-
vated chloride ion channel activity [8]. Signiﬁcant readthrough was
achieved with aminoglycoside concentrations of 0.05–0.2 mg/ml.
The ﬁrst in vivo demonstration of aminoglycoside-induced read-
through was carried out in the DMD mouse model (mdx mouse)
[9]. Gentamicin (0.1–0.4 mg/ml) provided restoration of functional
dystrophin with increases in myotube size and number [9]. Other
genetic diseases in which aminoglycoside therapy has been applied
successfully include hemophilia and ataxia–talangiectasia [10,11].
More recently, the novel synthetic readthrough agent PTC124
(Ataluren) showed promising results in mdx mice with low levels
of toxicity [12].
The identiﬁcation and characterization of PTC readthrough-
inducing compounds necessitates the use of reporter systems.B.V. Open access under CC BY-NC-ND license.
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porter assay, and consists of a recoding sequence inserted between
ﬁreﬂy and renilla luciferase genes [13]. The ratio of the two lucifer-
ase activities provides a measure of translational efﬁciency associ-
ated with the test sequence. When a recoding event occurs (e.g.
readthrough of a stop codon), an increase in ﬁreﬂy luciferase activ-
ity is observed, but in the absence of such an event no activity is
observed. This system was successfully used to assess 1 and +1
frameshifting, as well as readthrough events [13]. Others have
adapted the system by modifying the recoding sequence according
to the gene of interest, e.g. APC [14] or DMD [15].
Here we describe the generation and characterization of a green
ﬂuorescent protein (GFP) reporter for PTC readthrough assessment
(pMHG-W57⁄). Unlike, gene-speciﬁc reporters the recoding event
in pMHG-W57⁄ occurs in the reporter protein (i.e. GFP). Thus, the
reporter may be used as a general indicator of PTC readthrough
in cell culture models. pMHG-W57⁄ can be useful for optimizing
readthrough conditions when many types of recoding events are
possible, e.g. nonsense and frameshift mutations in cancer cells.
2. Materials and methods
2.1. Generation of pMHG-W57⁄ reporter
A GFP (S65T redshifted variant)-containing plasmid, pMONO-
hygro-gfp (pMHG) (Invivogen, San Diego, CA) was used for the gen-
eration of the readthrough reporter. The plasmid contains a ferritin
heavy chain (FerH) promoter fused to the SV40 enhancer at its 50
end and the mouse elongation factor 1 alpha gene at its 30 end.
Hygromycin B resistance is provided by the Escherichia coli phos-
photransferase gene hph. Site-directed mutagenesis of GFP trypto-
phan 57 codon to a stop codon (W57⁄) (G171A, mRNA) was carried
out using the Quikchange XL mutagenesis kit (Stratagene, La Jolla,
CA) according to the manufacturer’s guidelines. An opal stop codon
(TGA) was introduced using the following primers (forward, G CTG
CCA GTG CCT TGA CCA ACT CTG GTG AC; reverse, GTC ACC AGA
GTT GGT CAA AGG CAC TGG CAG C). The W57⁄ mutation in
pMHG-W57⁄ was conﬁrmed by direct sequencing.
2.2. Cell culture and transient transfections
HCT-116 colorectal cancer cells were obtained from the Ameri-
can Tissue Type Collection and maintained in McCoy’s 5A media
supplemented with 10% fetal bovine serum. Cells were passaged
every 2–3 days. Cells were seeded in 96-wells plates (3  104/well)
or 12-well plates (2  105/well) 24 h prior to transfection. Cells
were transfected using lipofectamine 2000 (Invitrogen, Carlsbad,
CA) reagent with pMHG or pMHG-W57⁄ (320 ng/well DNA for
96-well plate and 1.6 lg/well DNA for 12-well plate). After 24 h,
cell media was removed and cells were treated with Geneticin
(G-418) (0–2000 lg/ml) for 24 h. GFP in transfected cells was im-
aged using a Zeiss Axiovert 25 inverted microscope (Carl Zeiss,
Thornwood, NY) with a ﬂuorescein isothiocyanate (FITC) ﬁlter at
50 magniﬁcation. A Zeiss Axiocam MR camera was used to cap-
ture ﬂuorescent cell images.
2.3. Flow cytometry
After transfection and treatment cells were cells were detached
from plates using trypsin and resuspended in McCoy’s 5A media.
Green ﬂuorescent cells in pMHG/pMHG-W57⁄ transfected cells
were quantiﬁed using a LSRII ﬂow cytometer (BD Biosciences,
San Hose, CA), running FACSDiva software (v 6.1.2). A negative con-
trol (non-transfected, non-treated cells) and a positive control
(pMHG transfected cells) were used to optimize voltages anddetection thresholds for GFP ﬂuorescence. Two biological repli-
cates were analyzed for each condition.
3. Results
3.1. pMHG-W57⁄ reporter generation
Assessment of chemically-induced PTC readthrough is enabled
by the use of reporter systems. Most PTC readthrough reporter
constructs contain a recoding sequence which lies upstream of a
reporter enzyme such as luciferase. This approach requires the
generation of a new construct containing a recoding sequence spe-
ciﬁc to each gene of interest, as well as each recoding event in that
gene (e.g. DMD, CFTR). However, if multiple recoding events occur
in a single biological system, it may be more advantageous to use a
more general readthrough reporter. Therefore, we generated a PTC
readthrough reporter, pMHG-W57⁄, which can be used as a general
indicator of readthrough efﬁciency. A PTC mutation has been intro-
duced into the coding sequence of GFP (W57⁄). In the absence of
translational readthrough a truncated non-functional protein is
generated, while readthrough results in fully functional, ﬂuores-
cent GFP (Fig. 1). Therefore, global readthrough can be tested by
parallel transient transfection of pMHG-W57⁄ and pMHG (wild-
type GFP). GFP ﬂuorescence in pMHG-W57⁄ treated cells can be
normalized to pMHG ﬂuorescence in order to calculate read-
through efﬁciency.
3.2. Fluorescence imaging of pMHG-W57⁄ transfected cells
HCT-116 colorectal cancer cells were transiently transfected
with either pMHG or pMHG-W57⁄ and subsequently treated
with increasing concentrations of G-418 (0–2000 lg/ml). Cells
were examined by ﬂuorescence microscopy. No ﬂuorescent cells
were observed in untreated pMHG-W57⁄ transfected cells. In
G-418-treated, pMHG-W57⁄-transfected cells a dose-dependent
increase in ﬂuorescent cells was observed (Fig. 2). The highest
G-418 concentration (2000 lg/ml) generated the largest number
of ﬂuorescent cells, but less than observed in pMHG-transfected
cells, indicating that chemically-induced readthrough is relatively
inefﬁcient.
3.3. Quantitative assessment of readthrough by ﬂow cytometry
In order to provide a relative quantitative assessment of read-
through efﬁciency in G-418-treated, pMHG-W57⁄ transfected cells,
GFP-positive cells were quantiﬁed by ﬂow cytometry. As before, a
dose-dependent increase in GFP-positive cells was seen in G-418-
treated cell cultures. In pMHG-W57⁄-transfected cells, maximum
readthrough (5.5% GFP positive) was achieved at the 2000 lg/ml
G-418 level (Fig. 3A). Signiﬁcantly higher levels of GFP-positive
cells were observed in pMHG-transfected cells (26.5%). When read-
through levels in G-418-treated cells are normalized to pMHG lev-
els, readthrough efﬁciencies ranged between 1% (20 lg/ml) and
20% (2000 lg/ml) (Fig. 3B). This result is in general agreement with
previously reported efﬁciencies for chemically induced read-
through in cultured cells. The data demonstrate that pMHG-
W57⁄ can serve as a sensitive, quantitative reporter for PTC read-
through and is capable of detecting dose-dependent recoding of
PTCs in cultured cells.
4. Discussion
Chemically induced readthrough of PTCs has become a widely
adopted strategy for the restoration of normal protein expression
in several human genetic disorders [7] and a tool to identify genes
Fig. 1. Schematic representation of pMHG-W57⁄ reporter for premature termination codon (PTC) readthrough.
Fig. 2. Assessment of chemically-induced readthrough by G-418 in pMHG-W57⁄-
transfected cells by ﬂuorescence microscopy. HCT-116 cells were transiently
transfected with pMHG-W57⁄ or pMHG (wildtype) for 24 h and then treated with
G-418 (20–2000 lg/ml) for a further 24 h.
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in relatively low levels of restoration, in many diseases this may be
sufﬁcient to cause signiﬁcant clinical improvements. This is espe-
cially true of recessive disorders where the protein of interest is
usually absent. Several studies have demonstrated the utility of
aminoglycosides as readthrough inducers in conditions such asCF, DMD and hemophilia [9,10,13]. However, at high doses amino-
glycosides may interfere with normal protein translation, resulting
in signiﬁcant toxicity. Therefore, establishing sub-toxic, therapeu-
tic concentrations is critical for the development of readthrough
reagents.
Here we describe a novel reporter system, pMHG-W57⁄, for the
assessment of PTC readthrough in cultured cells which can be used
to aid in the characterization and investigation of readthrough re-
agents. Most reporter plasmids contain a recoding sequence spe-
ciﬁc to the gene under investigation, as well as a reporter
enzyme whose expression is indicative of a readthrough event. In
pMHG-W57⁄, the recoding event occurs in the reporter protein
(GFP), thus obviating the need for a gene-speciﬁc recoding se-
quence. We have successfully demonstrated by ﬂuorescence
microscopy and ﬂow cytometry that pMHG-W57⁄ detected read-
through over a range of G-418 concentrations (20–2000 lg/ml)
and that GFP positive cells increased in a dose-dependent manner.
Further experiments will be required to see how pMHG-W57⁄ per-
forms with readthrough drugs other than G-418.
As a GFP-based reporter, pMHG-W57⁄ offers several advantages
over conventional luciferase-based readthrough reporters. Read-
through may be assessed directly in intact cells by ﬂuorescence
microscopy or ﬂow cytometry. After readthrough measurement,
cells can be sorted and collected, allowing for further experimental
manipulation. Luciferase reporters require that cells be lysed and a
substrate is needed to generate luminescence, thus preventing fur-
ther analysis of the intact cells.
Because a gene-speciﬁc resequencing code is not required by
pMHG-W57⁄, it can be used as a general indicator to test
compounds for NMD-inhibition and to compare cell lines for read-
through competency. For example, in cancer cells gene identiﬁca-
tion by NMD inhibition (GINI) has been used to detect genes
containing inactivating mutations [3]. By preventing NMD-
mediated degradation of PTC-containing transcripts, novel can-
cer-related mutations may be identiﬁed [4–6]. NMD suppression
Fig. 3. Quantitative evaluation of readthrough by ﬂow cytometry. (A) HCT-116 cells
were transiently transfected with pMHG-W57⁄ or pMHG (wildtype) for 24 h and
then treated with G-418 (20–2000 lg/ml) for a further 24 h. GFP positive cells were
quantiﬁed by ﬂow cytometry. (B) GFP positive cell numbers in G-418-treated,
pMHG-W57⁄-transfected cells were normalized to pMHG-transfected cell number
in order to estimate readthrough efﬁciency values.
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would allow novel mutants to be detected at the protein level. It
should be noted that gene-speciﬁc reporters may be better suited
for the assessment of readthrough when sequence context is a ma-
jor factor in determining efﬁciency. Nonetheless, the use of a gen-
eral readthrough indicator such as our GFP-based model could
help in the screening of novel compounds and in optimization of
treatment conditions.In conclusion, we generated a reporter construct which is capa-
ble of detecting dose-dependent chemically-induced PTC read-
through in viable cultured cells. The use of a GFP-based reporter
which does not require gene-speciﬁc recoding sequence may offer
several advantages over luciferase-based reporters.
Acknowledgement
This work was supported by NIH Grant U24 CA126479.
References
[1] OMIM – Online Mendelian Inheritance in Man. National Center for
Biotechnology Information.
[2] The Leiden DMD mutation database. Center for Human and Clinical Genetics,
Leiden University Medical Center.
[3] Noensie, E.N. and Dietz, H.C. (2001) A strategy for disease gene identiﬁcation
through nonsense-mediated mRNA decay inhibition. Nat. Biotechnol. 19, 434–
439.
[4] Bloethner, S., Mould, A., Stark, M. and Hayward, N.K. (2008) Identiﬁcation of
ARHGEF17, DENND2D, FGFR3, and RB1 mutations in melanoma by inhibition
of nonsense-mediated mRNA decay. Genes Chromosom. Cancer 47, 1076–
1085.
[5] Huusko, P. et al. (2004) Nonsense-mediated decay microarray analysis
identiﬁes mutations of EPHB2 in human prostate cancer. Nat. Genet. 36,
979–983.
[6] Ionov, Y., Nowak, N., Perucho, M., Markowitz, S. and Cowell, J.K. (2004)
Manipulation of nonsense mediated decay identiﬁes gene mutations in colon
cancer cells with microsatellite instability. Oncogene 23, 639–645.
[7] Zingman, L.V., Park, S., Olson, T.M., Alekseev, A.E. and Terzic, A. (2007)
Aminoglycoside-induced translational read-through in disease: overcoming
nonsense mutations by pharmacogenetic therapy. Clin. Pharmacol. Ther. 81,
99–103.
[8] Howard, M., Frizzell, R.A. and Bedwell, D.M. (1996) Aminoglycoside antibiotics
restore CFTR function by overcoming premature stop mutations. Nat. Med. 2,
467–469.
[9] Barton-Davis, E.R., Cordier, L., Shoturma, D.I., Leland, S.E. and Sweeney, H.L.
(1999) Aminoglycoside antibiotics restore dystrophin function to skeletal
muscles of mdx mice. J. Clin. Invest. 104, 375–381.
[10] James, P.D., Raut, S., Rivard, G.E., Poon, M.C., Warner, M., McKenna, S., Leggo, J.
and Lillicrap, D. (2005) Aminoglycoside suppression of nonsense mutations in
severe hemophilia. Blood 106, 3043–3048.
[11] Lai, C.H., Chun, H.H., Nahas, S.A., Mitui, M., Gamo, K.M., Du, L. and Gatti, R.A.
(2004) Correction of ATM gene function by aminoglycoside-induced read-
through of premature termination codons. Proc. Natl. Acad. Sci. USA 101,
15676–15681.
[12] Welch, E.M. et al. (2007) PTC124 targets genetic disorders caused by nonsense
mutations. Nature 447, 87–91.
[13] Grentzmann, G., Ingram, J.A., Kelly, P.J., Gesteland, R.F. and Atkins, J.F. (1998) A
dual-luciferase reporter system for studying recoding signals. RNA 4, 479–
486.
[14] Zilberberg, A., Lahav, L. and Rosin-Arbesfeld, R. (2010) Restoration of APC gene
function in colorectal cancer cells by aminoglycoside- and macrolide-induced
read-through of premature termination codons. Gut 59, 496–507.
[15] Howard, M.T., Shirts, B.H., Petros, L.M., Flanigan, K.M., Gesteland, R.F. and
Atkins, J.F. (2000) Sequence speciﬁcity of aminoglycoside-induced stop
condon readthrough: potential implications for treatment of Duchenne
muscular dystrophy. Ann. Neurol. 48, 164–169.
